- Home
- Publications
- Publication Search
- Publication Details
Title
Pioglitazone, Bladder Cancer, and the Presumption of Innocence
Authors
Keywords
-
Journal
Current Drug Safety
Volume 17, Issue 4, Pages 294-318
Publisher
Bentham Science Publishers Ltd.
Online
2022-03-07
DOI
10.2174/1574886317666220304124756
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Increased DNA strand breaks and neoplastic transformation in human bladder cells treated with pioglitazone
- (2021) Zülal Atlı ŞekeroĞlu et al. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
- Pioglitazone and bladder cancer: improving research methods
- (2020) E. Ripamonti et al. DIABETIC MEDICINE
- Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome
- (2020) Georgios S. Papaetis et al. CLINICAL DRUG INVESTIGATION
- Pioglitazone Reduces Mortality and Adverse Events in Patients With Type 2 Diabetes and With Advanced Chronic Kidney Disease: National Cohort Study
- (2020) Chieh-Li Yen et al. DIABETES CARE
- Activation of PPARγ and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells
- (2020) Aaron A. Mehus et al. PLoS One
- Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials
- (2020) Binayak Sinha et al. Scientific Reports
- Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018
- (2020) Clemens Engler et al. BMJ Open Diabetes Research & Care
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysis
- (2020) Simona Panunzi et al. DIABETES OBESITY & METABOLISM
- Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes
- (2020) Teresa Vanessa Fiorentino et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Empagliflozin and the Diabetic Kidney: Pathophysiological Concepts and Future Challenges
- (2020) Georgios S. Papaetis Endocrine Metabolic & Immune Disorders-Drug Targets
- Update on bladder cancer molecular subtypes
- (2020) Megan Hoi Yan Fong et al. Translational Andrology and Urology
- Recurrent activating mutations of PPARγ associated with luminal bladder tumors
- (2019) Natacha Rochel et al. Nature Communications
- High Glucose with Insulin Induces Cell Cycle Progression and Activation of Oncogenic Signaling of Bladder Epithelial Cells Cotreated with Metformin and Pioglitazone
- (2019) Daejin Kim et al. Journal of Diabetes Research
- Pioglitazone Therapy in Patients With Stroke and Prediabetes
- (2019) J. David Spence et al. JAMA Neurology
- PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells
- (2019) Songtao Cheng et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes
- (2019) Ralph A DeFronzo et al. Diabetes & Vascular Disease Research
- PPARγ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway
- (2019) Shidong Lv et al. BMC CANCER
- Study Design Choices for Evaluating Comparative Safety of Diabetic Medications: An Evaluation of Pioglitazone and Bladder Cancer Risk Among Older US Adults with Type‐2 Diabetes
- (2019) Elizabeth M. Garry et al. DIABETES OBESITY & METABOLISM
- Glucose‐lowering medications and the risk of cancer: A methodological review of studies based on real‐world data
- (2019) Katsiaryna Bykov et al. DIABETES OBESITY & METABOLISM
- Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer
- (2019) Songtao Cheng et al. CLINICAL SCIENCE
- Heterogeneity of PTEN and PPAR‑γ in cancer and their prognostic application to bladder cancer
- (2019) Zhouzhou Zhang et al. Experimental and Therapeutic Medicine
- Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells
- (2019) Chang Liu et al. Nature Communications
- Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records
- (2018) Elisabetta Patorno et al. DIABETES OBESITY & METABOLISM
- An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug’s effect on cardiovascular disease and non-alcoholic steatohepatitis
- (2018) Mayer B. Davidson et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity
- (2018) Saghar Yousefnia et al. GENE
- Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study
- (2018) Shao-ling Yang et al. International Journal of Medical Sciences
- Evaluation of Uracil, Sodium Ascorbate, and Rosiglitazone as Promoters of Urinary Bladder Transitional Cell Carcinomas in Male Sprague-Dawley Rats
- (2018) Mark Tirmenstein et al. TOXICOLOGIC PATHOLOGY
- Pioglitazone and bladder cancer risk: a systematic review and meta-analysis
- (2018) Huilin Tang et al. Cancer Medicine
- Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis
- (2018) Huaqing Yan et al. Cancer Management and Research
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- A systematic review of observational studies of the association between pioglitazone use and bladder cancer
- (2018) E. Ripamonti et al. DIABETIC MEDICINE
- Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
- (2018) Bancha Satirapoj et al. PLoS One
- Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis
- (2017) Zhuyue Li et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
- (2017) Manav Korpal et al. Nature Communications
- Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes
- (2017) Hua Qu et al. Scientific Reports
- Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis
- (2017) Hung-Wei Liao et al. BMJ Open
- Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
- (2017) Olga Vaccaro et al. Lancet Diabetes & Endocrinology
- Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
- (2017) Elena Filipova et al. Diabetes Therapy
- Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
- (2017) Elena Filipova et al. Diabetes Therapy
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
- (2016) E. Erdmann et al. DIABETES OBESITY & METABOLISM
- Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor
- (2016) R. A. DeFronzo et al. DIABETES OBESITY & METABOLISM
- Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW
- (2016) Devjit Tripathy et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence
- (2016) Mayer B. Davidson JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes
- (2016) Eugene Han et al. MEDICINE
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- (2016) Walter N. Kernan et al. NEW ENGLAND JOURNAL OF MEDICINE
- PPARγ signaling and emerging opportunities for improved therapeutics
- (2016) Shuibang Wang et al. PHARMACOLOGICAL RESEARCH
- Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus
- (2016) Anh Vu et al. PHARMACOTHERAPY
- Pioglitazone for Secondary Stroke Prevention
- (2016) Meng Lee et al. STROKE
- Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries
- (2016) Pasi Korhonen et al. BMJ-British Medical Journal
- Pioglitazone use and risk of bladder cancer: population based cohort study
- (2016) Marco Tuccori et al. BMJ-British Medical Journal
- PPARγ; and Its Ligands: Potential Antitumor Agents in the Digestive System
- (2016) Linjing Shu et al. Current Stem Cell Research & Therapy
- Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries
- (2016) Pasi Korhonen et al. BMJ-British Medical Journal
- Pioglitazone use and risk of bladder cancer: population based cohort study
- (2016) Marco Tuccori et al. BMJ-British Medical Journal
- Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study
- (2016) Todd A. Mackenzie et al. Diabetes Therapy
- Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study
- (2016) Todd A. Mackenzie et al. Diabetes Therapy
- Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use
- (2016) Vipulkumar Dadhania et al. EBioMedicine
- Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway
- (2016) Gang Wang et al. Scientific Reports
- State of the art paper Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns
- (2015) Georgios S. Papaetis et al. Archives of Medical Science
- Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study
- (2015) Maurizio Montella et al. BMC CANCER
- Evaluation of the Long-Term Durability and Glycemic Control of Fasting Plasma Glucose and Glycosylated Hemoglobin for Pioglitazone in Japanese Patients with Type 2 Diabetes
- (2015) Frances Stringer et al. Diabetes Technology & Therapeutics
- Pioglitazone: are rumours of its death exaggerated?
- (2015) E. A. M. Gale DIABETIC MEDICINE
- Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter
- (2015) R. E. J. Ryder DIABETIC MEDICINE
- Pioglitazone: reports of its death are greatly exaggerated - it is alive and ready to resume saving lives
- (2015) R. E. J. Ryder DIABETIC MEDICINE
- Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
- (2015) James D. Lewis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study
- (2015) Ryota Tanaka et al. Journal of Atherosclerosis and Thrombosis
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
- (2014) Daniel Levin et al. DIABETOLOGIA
- Effects of Pioglitazone on Macrovascular Events in Patients with Type 2 Diabetes Mellitus at High Risk of Stroke: The PROFIT-J Study
- (2014) Hidenori Yoshii et al. Journal of Atherosclerosis and Thrombosis
- Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study
- (2014) H. C. Lin et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study
- (2014) Sang-Man Jin et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer
- (2014) James D. Lewis et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- The Association of Pioglitazone and Urinary Tract Disease in Type 2 Diabetic Taiwanese: Bladder Cancer and Chronic Kidney Disease
- (2014) Mei-Yueh Lee et al. PLoS One
- EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype
- (2014) S. Rebouissou et al. Science Translational Medicine
- Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes
- (2014) Anne Biton et al. Cell Reports
- Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials
- (2013) Matteo Monami et al. ACTA DIABETOLOGICA
- Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan
- (2013) Chin-Hsiao Tseng BMC CANCER
- Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies
- (2013) Zhaowei Zhu et al. BMC CANCER
- Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis
- (2013) Richard M. Turner et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Comparing Pioglitazone to Insulin with Respect to Cancer, Cardiovascular and Bone Fracture Endpoints, Using Propensity Score Weights
- (2013) Carlos Vallarino et al. CLINICAL DRUG INVESTIGATION
- Pioglitazone and Cancer: Angel or Demon?
- (2013) Michael Kostapanos et al. CURRENT PHARMACEUTICAL DESIGN
- Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus
- (2013) G. E. C. Sun et al. DIABETES OBESITY & METABOLISM
- Observational follow-up of the PROactive study: a 6-year update
- (2013) E. Erdmann et al. DIABETES OBESITY & METABOLISM
- Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies
- (2013) M. Ferwana et al. DIABETIC MEDICINE
- Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?
- (2013) Jean-Luc Faillie et al. DRUG SAFETY
- Risk of Bladder Cancer in Diabetic Patients Treated with Rosiglitazone or Pioglitazone: A Nested Case–Control Study
- (2013) Fei-Yuan Hsiao et al. DRUG SAFETY
- Peroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies
- (2013) CHIN-HSIAO TSENG et al. JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS
- Pioglitazone use and the risk of bladder cancer
- (2013) Hsin-Wei Kuo et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Carcinogenicity of some drugs and herbal products
- (2013) Yann Grosse et al. LANCET ONCOLOGY
- Cancer Risk for Patients Using Thiazolidinediones for Type 2 Diabetes: A Meta-Analysis
- (2013) C. Bosetti et al. ONCOLOGIST
- A Novel Mechanism of PPAR Gamma Induction via EGFR Signalling Constitutes Rational for Combination Therapy in Bladder Cancer
- (2013) Jose Joao Mansure et al. PLoS One
- Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis
- (2013) Shiyao He et al. TUMOR BIOLOGY
- Pioglitazone, bladder cancer, and detection bias (吡格列酮、膀胱癌以及检验偏差)
- (2013) Paul Dolin Journal of Diabetes
- Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure
- (2013) Jeremy J Walker et al. Lancet Diabetes & Endocrinology
- A population-based cohort study in Taiwan––use of insulin sensitizers can decrease cancer risk in diabetic patients?
- (2012) C.-H. Kao et al. ANNALS OF ONCOLOGY
- Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors
- (2012) Aramesh Saremi et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Pioglitazone and bladder cancer: a propensity score matched cohort study
- (2012) Li Wei et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents
- (2012) S. La Maestra et al. CARCINOGENESIS
- Thiazolidinedione use and cancer incidence in type 2 diabetes: A systematic review and meta-analysis
- (2012) I.N. Colmers et al. DIABETES & METABOLISM
- Metformin and the Risk of Cancer: Time-related biases in observational studies
- (2012) S. Suissa et al. DIABETES CARE
- Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis
- (2012) Zhaowei Zhu et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes
- (2012) Kanta Fujimoto et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Pioglitazone and risk of bladder cancer: clarification of the design of the French study
- (2012) A. T. Perez DIABETOLOGIA
- Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
- (2012) A. Neumann et al. DIABETOLOGIA
- Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
- (2012) H. M. Colhoun et al. DIABETOLOGIA
- Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study
- (2012) Ronac Mamtani et al. JNCI-Journal of the National Cancer Institute
- Role of Peroxisome Proliferator Activated Receptor-Gamma in Bacillus Calmette-Guérin Bladder Cancer Therapy
- (2012) Yanina Langle et al. JOURNAL OF UROLOGY
- Meta-analysis confirms raised risk of bladder cancer from pioglitazone
- (2012) B. Kermode-Scott BMJ-British Medical Journal
- The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study
- (2012) L. Azoulay et al. BMJ-British Medical Journal
- The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
- (2012) Sun Ok Song et al. Diabetes & Metabolism Journal
- Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit
- (2011) Georgios S. Papaetis et al. CURRENT DRUG TARGETS
- Pioglitazone and Bladder Cancer: A population-based study of Taiwanese
- (2011) C.-H. Tseng DIABETES CARE
- Comment: Analyses Using Time-Dependent Pioglitazone Usage in Cox Models May Lead to Wrong Conclusions About Its Association With Cancer
- (2011) Xilin Yang et al. DIABETES CARE
- Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes
- (2011) A. Ferrara et al. DIABETES CARE
- Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study
- (2011) J. D. Lewis et al. DIABETES CARE
- Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
- (2011) C. Piccinni et al. DIABETES CARE
- Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan
- (2011) C.-H. Tseng DIABETOLOGIA
- Successful Treatment of Prediabetes in Clinical Practice: Targeting Insulin Resistance and β-Cell Dysfunction
- (2011) John Armato et al. Endocrine Practice
- Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus
- (2011) Chia-Hsuin Chang et al. HEPATOLOGY
- Association Between Smoking and Risk of Bladder Cancer Among Men and Women
- (2011) Neal D. Freedman JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pioglitazone and bladder cancer
- (2011) Dominique Hillaire-Buys et al. LANCET
- Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
- (2011) Ralph A. DeFronzo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats
- (2011) Keiichiro Sato et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis
- (2010) Pantelis A. Sarafidis et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Diabetes and risk of bladder cancer
- (2010) Todd MacKenzie et al. CANCER
- Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity
- (2009) Kohei Kaku et al. CURRENT MEDICAL RESEARCH AND OPINION
- Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes
- (2009) John Dormandy et al. DRUG SAFETY
- PPARs and adipocyte function
- (2009) Constantinos Christodoulides et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Effects of Pioglitazone, a Peroxisome Proliferator–Activated Receptor Gamma Agonist, on the Urine and Urothelium of the Rat
- (2009) Shugo Suzuki et al. TOXICOLOGICAL SCIENCES
- Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARα+γAgonists
- (2009) Martin B. Oleksiewicz et al. PPAR Research
- Impact of peripheral arterial disease in patients with diabetes—Results from PROactive (PROactive 11)
- (2008) J.A. Dormandy et al. ATHEROSCLEROSIS
- Effects of PPAR agonists on proliferation and differentiation in human urothelium
- (2008) Claire L. Varley et al. EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY
- Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers
- (2008) Ronald A. Lubet et al. INTERNATIONAL JOURNAL OF CANCER
- The Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-α–Dependent Manner In Vitro and In Vivo in Mice
- (2008) Gabriela Orasanu et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event
- (2008) Gerald G. Long et al. TOXICOLOGIC PATHOLOGY
- Histopathology of the Urinary Bladders of Cynomolgus Monkeys Treated with PPAR Agonists
- (2008) Jerry F. Hardisty et al. TOXICOLOGIC PATHOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started